Bcl-2 Antisense Oligodeoxynucleotide G3139 and Paclitaxel in Treating Patients With Recurrent Small Cell Lung Cancer
Public ClinicalTrials.gov record NCT00005032. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase I/II Study of G3139, a BCL-2 Antisense Oligonucleotide, Combined With Paclitaxel for the Treatment of Recurrent Small Cell Lung Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Bcl-2 antisense oligodeoxynucleotide G3139 may increase the effectiveness of a chemotherapy drug by making tumor cells more sensitive to the drug. PURPOSE: Phase I/II trial to study the effectiveness of bcl-2 antisense oligodeoxynucleotide G3139 and paclitaxel in treating patients who have recurrent small cell lung cancer.
Study identification
- NCT ID
- NCT00005032
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 12 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 2000 (Type not available)
- Primary completion
- Jan 2001 (Actual)
- Completion
- Sep 2001 (Actual)
- Last update posted
- Feb 11, 2013
2000 – 2001
United States locations
- U.S. sites
- 11
- U.S. states
- 3
- U.S. cities
- 9
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Illinois at Chicago | Chicago | Illinois | 60612 | — |
| University of Chicago Cancer Research Center | Chicago | Illinois | 60637 | — |
| Louis A. Weiss Memorial Hospital | Chicago | Illinois | 60640 | — |
| Cancer Care Specialists of Central Illinois, S.C. | Decatur | Illinois | 62526 | — |
| Evanston Northwestern Health Care | Evanston | Illinois | 60201 | — |
| Division of Hematology/Oncology | Park Ridge | Illinois | 60068 | — |
| Oncology/Hematology Associates of Central Illinois, P.C. | Peoria | Illinois | 61602 | — |
| Central Illinois Hematology Oncology Center | Springfield | Illinois | 62701 | — |
| Fort Wayne Medical Oncology and Hematology, Inc. | Fort Wayne | Indiana | 46885-5099 | — |
| Michiana Hematology/Oncology P.C. | South Bend | Indiana | 46617 | — |
| Arthur G. James Cancer Hospital - Ohio State University | Columbus | Ohio | 43210 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00005032, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 11, 2013 · Synced Oct 24, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00005032 live on ClinicalTrials.gov.